RE:No news yet on IV Push and ChinaI agree with the NY celebration comment. Likely going to be a while before any parnter news due to that. However, your comment about IP got me thinking. I would not want to parner in Oncology at this stage as it isnt very expensive and there is significant opportunity to move up the value chain and get a better offer if the science is strong. On the onther hand, Egrifta in Nash would be a great candidate. The old formulation is already being ripped off and sold to body builders, there is a relatively short patent window (after factoring in time to get to market), and the cost of Phase 3 may be significant. So why not partner on an asset like this? If the partner is willing to pay and move things along then I see no issue as the risks are real and material. The other option is to sit on our hands and let the clock run out as we dont have the funds to do both.